ENTO

Entero Therapeutics, Inc. (ENTO) Risks & Opportunities Analysis (2026)

Invetso Score: 3.6/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Risks

Score: 2.8 (Weak)

Liquidity appears extremely tight versus peers, with a 0.16 current ratio and negative interest coverage, increasing refinancing and operating-flexibility risk if demand softens.

Working-capital efficiency is severely stretched, as a 708-day cash conversion cycle and 1,028-day receivables collection lag peers and can constrain growth funding.

Negative net debt to EBITDA looks superficially favorable, but the combination of weak coverage and liquidity suggests balance-sheet capacity is less resilient than better-capitalized peers.

The very high days sales outstanding implies customer payment delays or concentrated receivables risk, which can pressure cash generation more than in faster-turning peer models.

Opportunities

Score:

Low reported debt-to-equity and near-zero net debt provide some balance-sheet optionality versus leveraged peers if cash collection improves and liquidity normalizes.

If receivables convert faster, the large working-capital release could materially improve cash flow and funding capacity relative to peers with steadier but less levered profiles.

The absence of meaningful financial leverage may allow ENTO to preserve strategic flexibility better than debt-heavy peers during a demand recovery, provided operating cash flow stabilizes.

Overall Score

Score:

ENTO’s forward positioning is constrained by severe liquidity and working-capital stress that outweigh modest balance-sheet optionality, leaving it weaker than most peers despite low reported leverage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Entero Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →